Glucagon-like peptide-1 receptor agonists as a disease-modifying therapy for knee osteoarthritis mediated by weight loss: findings from the Shanghai Osteoarthritis Cohort
Open accessThe DOI matches its Crossref record; 19 of the 19 references it cites were found in a registry or an index.
Abstract
OBJECTIVE: Obesity is a risk factor for knee osteoarthritis (KOA) development and progression. Glucagon-like peptide-1 receptor agonists (GLP-1RAs) are indicated for type 2 diabetes mellitus (T2DM) and obesity. However, whether KOA patients can benefit from GLP-1RA therapies has not been sufficiently investigated, especially in the long term. METHODS: The Shanghai Osteoarthritis Cohort study is a prospective, observational, multicentre study of >40 000 adults with clinically diagnosed osteoarthritis aged >45 years in Shanghai. We identified all KOA participants with comorbid T2DM enrolled from 1 January 2011 to 1 January 2017. Primary outcome was incidence of knee surgery after enrolment. Secondary outcomes included pain-relieving medication use, number of intra-articular therapies, Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) and medial femorotibial joint cartilage thickness. To evaluate the effects of GLP-1RA, we performed before-and-after comparison and comparison with participants who had no GLP-1RA exposure. RESULTS: For an intergroup comparison (non-GLP-1RA vs GLP-1RA), more weight loss (adjusted mean difference in weight change from baseline -7.29 kg (95% CI -8.07 to -6.50 kg), p<0.001) and lower incidence of knee surgery (93/1574 (5.9%) vs 4/233 (1.7%), adjusted p=0.014) were observed in the GLP-1RA group. Statistically significant differences in mean change from baseline for the WOMAC total and pain subscale scores were observed (adjusted mean difference in WOMAC total score -1.46 (95% CI -2.84 to -0.08), p=0.038; adjusted mean difference in WOMAC pain subscore -3.37 (95% CI -5.79 to -0.94), p=0.007). Cartilage-loss velocity of the medial femorotibial joint was significantly lower in the GLP-1RA group postadjustment for baseline characteristics (adjusted mean difference -0.02 mm (95% CI -0.03 to -0.002 mm), p=0.004). For the before-and-after comparison within the GLP-1RA group, we observed a significant decrease of symptom-relieving medication consumption and cartilage loss velocity of medial femorotibial joint (after-treatment vs before-treatment: -0.03±0.05 vs -0.05±0.07 mm/year, p<0.001). The association between GLP-1RA exposure and decreased incidence of knee surgery was mediated by weight reduction (mediation proportion: 32.1%), instead of glycaemic control (too small to calculate). CONCLUSION: With sufficient treatment duration, GLP-1RA therapies might be disease-modifying for KOA patients with comorbid T2DM, possibly mediated by weight loss. Further investigation is needed to elucidate effects of GLP-1RA on disease process, joint structure and patient-reported outcomes of osteoarthritis.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Murray, C. J. L., Aravkin, A. Y., Zheng, P., Abbafati, C., Abbas, K. M., Abbasi-Kangevari, M., Abd-Allah, F., Abdelalim, A., Abdollahi, M., Abdollahpour, I., et al. (2020) · The Lancet · doi:10.1016/s0140-6736(20)30752-2 · Cited by 9,854
Once-Weekly Semaglutide in Adults with Overweight or Obesity
Wilding, J. P. H., Batterham, R. L., Calanna, S., Davies, M., Van Gaal, L. F., Lingvay, I., McGowan, B. M., Rosenstock, J., Tran, M. T. D., Wadden, T. A., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2032183 · Cited by 5,205
A general approach to causal mediation analysis.
Imai, K., Keele, L., & Tingley, D. (2010) · Psychological Methods · doi:10.1037/a0020761 · Cited by 4,143
A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management
Pi-Sunyer, X., Astrup, A., Fujioka, K., Greenway, F., Halpern, A., Krempf, M., Lau, D. C. W., le Roux, C. W., Violante Ortiz, R., Jensen, C. B., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1411892 · Cited by 2,724
Kolasinski, S. L., Neogi, T., Hochberg, M. C., Oatis, C., Guyatt, G., Block, J., Callahan, L., Copenhaver, C., Dodge, C., Felson, D., et al. (2020) · Arthritis Care & Research · doi:10.1002/acr.24131 · Cited by 2,516
Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes
Frías, J. P., Davies, M. J., Rosenstock, J., Pérez Manghi, F. C., Fernández Landó, L., Bergman, B. K., Liu, B., Cui, X., & Brown, K. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2107519 · Cited by 2,096
Garvey, W. T., Mechanick, J. I., Brett, E. M., Garber, A. J., Hurley, D. L., Jastreboff, A. M., Nadolsky, K., Pessah-Pollack, R., & Plodkowski, R. (2016) · Endocrine Practice · doi:10.4158/ep161365.gl · Cited by 1,914
Obesity in adults: a clinical practice guideline
Wharton, S., Lau, D. C. W., Vallis, M., Sharma, A. M., Biertho, L., Campbell-Scherer, D., Adamo, K., Alberga, A., Bell, R., Boulé, N., et al. (2020) · Canadian Medical Association Journal · doi:10.1503/cmaj.191707 · Cited by 1,506
Wilding, J. P. H., Batterham, R. L., Davies, M., Van Gaal, L. F., Kandler, K., Konakli, K., Lingvay, I., McGowan, B. M., Oral, T. K., Rosenstock, J., et al. (2022) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.14725 · Cited by 1,128
Bray, G. A., Frühbeck, G., Ryan, D. H., & Wilding, J. P. H. (2016) · The Lancet · doi:10.1016/s0140-6736(16)00271-3 · Cited by 1,036
Research works printed but not linked: 40
- Hunter, 2014, The individual and socioeconomic impact of osteoarthritis, Nat Rev Rheumatol, 10, 437, 10.1038/nrrheum.2014.44 · DOI · Paper page
- Long, 2022, Prevalence trends of site-specific osteoarthritis from 1990 to 2019: findings from the global burden of disease study 2019, Arthritis & Rheumatology, 74, 1172, 10.1002/art.42089 · DOI · Paper page
- Reyes, 2016, Association between overweight and obesity and risk of clinically diagnosed knee, hip, and hand osteoarthritis: A population-based cohort study, Arthritis Rheumatol, 68, 1869, 10.1002/art.39707 · DOI · Paper page
- Arden, 2021, Non-surgical management of knee osteoarthritis: comparison of ESCEO and OARSI 2019 guidelines, Nat Rev Rheumatol, 17, 59, 10.1038/s41584-020-00523-9 · DOI · Paper page
- Fernandes, 2013, EULAR recommendations for the non-pharmacological core management of hip and knee osteoarthritis, Ann Rheum Dis, 72, 1125, 10.1136/annrheumdis-2012-202745 · DOI · Paper page
- Zhao, 2023, Global burden of osteoarthritis associated with high body mass index in 204 countries and territories, 1990-2019: findings from the global burden of disease study 2019, Endocrine, 79, 60, 10.1007/s12020-022-03201-w · DOI
- Liu, 2022, Disease burden of osteoarthritis of the knee and hip due to a high body mass index in China and the USA: 1990-2019 findings from the global burden of disease study 2019, BMC Musculoskelet Disord, 23, 63, 10.1186/s12891-022-05027-z · DOI
- Messier, 2022, Effect of diet and exercise on knee pain in patients with osteoarthritis and overweight or obesity: A randomized clinical trial, JAMA, 328, 2242, 10.1001/jama.2022.21893 · DOI
- Gudbergsen, 2021, Liraglutide after diet-induced weight loss for pain and weight control in knee osteoarthritis: a randomized controlled trial, Am J Clin Nutr, 113, 314, 10.1093/ajcn/nqaa328 · DOI · Paper page
- Yannakoulia, 2019, Dietary modifications for weight loss and weight loss maintenance, Metabolism, 92, 153, 10.1016/j.metabol.2019.01.001 · DOI · Paper page
- Neogi, 2013, Epidemiology of osteoarthritis, Rheum Dis Clin North Am, 39, 1, 10.1016/j.rdc.2012.10.004 · DOI · Paper page
- Kalra, 2021, Contemporary classification of glucagon-like peptide 1 receptor agonists (Glp1Ras), Diabetes Ther, 12, 2133, 10.1007/s13300-021-01113-y · DOI · Paper page
- Jafarzadeh, 2020, Mediating role of bone marrow lesions, Synovitis, pain sensitization, and depressive symptoms on knee pain improvement following substantial weight loss, Arthritis Rheumatol, 72, 420, 10.1002/art.41125 · DOI
- Reijman, 2004, Validity, reliability, and applicability of seven definitions of hip osteoarthritis used in Epidemiological studies: a systematic appraisal, Annals of the Rheumatic Diseases, 63, 226, 10.1136/ard.2003.010348 · DOI
- Skou, 2020, Comparison of three sets of clinical classification criteria for knee osteoarthritis: a cross-sectional study of 13,459 patients treated in primary care, Osteoarthritis and Cartilage, 28, 167, 10.1016/j.joca.2019.09.003 · DOI
- Wang, 2021, Diagnosis of early stage knee osteoarthritis based on early clinical course: data from the CHECK cohort, Arthritis Res Ther, 23, 217, 10.1186/s13075-021-02598-5 · DOI
- Clement, 2018, What is the minimum clinically important difference for the WOMAC index after TKA?, Clin Orthop Relat Res, 476, 2005, 10.1097/CORR.0000000000000444 · DOI · Paper page
- Bellamy, 2015, Development of multinational definitions of minimal clinically important improvement and patient acceptable symptomatic state in osteoarthritis, Arthritis Care & Research, 67, 972, 10.1002/acr.22538 · DOI
- Moseley, 2002, A controlled trial of Arthroscopic surgery for osteoarthritis of the knee, N Engl J Med, 347, 81, 10.1056/NEJMoa013259 · DOI · Paper page
- Sihvonen, 2020, Arthroscopic partial Meniscectomy for a degenerative Meniscus tear: a 5 year follow-up of the placebo-surgery controlled FIDELITY (Finnish degenerative Meniscus lesion study) trial, Br J Sports Med, 54, 1332, 10.1136/bjsports-2020-102813 · DOI
- Stahel, 2018, Surgeon practice patterns of Arthroscopic partial Meniscectomy for degenerative disease in the United States: A measure of low-value care, JAMA Surg, 153, 494, 10.1001/jamasurg.2017.6235 · doi:10.1001/jamasurg.2017.6235
- Rickert, 2020, On patient safety: Orthopaedic Surgeons must stop performing Arthroscopic partial Meniscectomy on patients with Arthritic knees, Clin Orthop Relat Res, 478, 28, 10.1097/CORR.0000000000001072 · doi:10.1097/corr.0000000000001072
- Eckstein, 2009, One year change of knee cartilage morphology in the first release of participants from the osteoarthritis initiative progression Subcohort: association with sex, body mass index, symptoms and radiographic osteoarthritis status, Ann Rheum Dis, 68, 674, 10.1136/ard.2008.089904 · DOI
- Eckstein, 2006, Double echo steady state magnetic resonance imaging of knee Articular cartilage at 3 Tesla: a pilot study for the osteoarthritis initiative, Annals of the Rheumatic Diseases, 65, 433, 10.1136/ard.2005.039370 · DOI · Paper page
- Boer, 2023, Obesity Pharmacotherapy: Incretin action in the central nervous system, Trends Pharmacol Sci, 44, 50, 10.1016/j.tips.2022.11.001 · DOI
- Leyland, 2016, Obesity and the relative risk of knee replacement surgery in patients with knee osteoarthritis: A prospective cohort study, Arthritis & Rheumatology, 68, 817, 10.1002/art.39486 · DOI
- Rosa, 2009, Impaired glucose Transporter-1 degradation and increased glucose transport and oxidative stress in response to high glucose in Chondrocytes from Osteoarthritic versus normal human cartilage, Arthritis Res Ther, 11, R80, 10.1186/ar2713 · DOI · Paper page
- Wang, 2021, Diabetes mellitus accelerates the progression of osteoarthritis in streptozotocin-induced diabetic mice by deteriorating bone Microarchitecture, bone mineral composition, and bone strength of Subchondral bone, Ann Transl Med, 9, 768, 10.21037/atm-20-6797 · DOI
- Schett, 2013, Diabetes is an independent Predictor for severe osteoarthritis: results from a longitudinal cohort study, Diabetes Care, 36, 403, 10.2337/dc12-0924 · DOI · Paper page
- Lu, 2018, Combination COX-2 inhibitor and metformin attenuate rate of joint replacement in osteoarthritis with diabetes: A nationwide, retrospective, matched-cohort study in Taiwan, PLoS ONE, 13, e0191242, 10.1371/journal.pone.0191242 · DOI
- Tingley, 2014, Mediation: R package for causal mediation analysis, J Stat Softw, 59, 10.18637/jss.v059.i05 · DOI · Paper page
- Mei, 2019, Liraglutide suppresses TNF-Α-induced degradation of extracellular matrix in human Chondrocytes: a therapeutic implication in osteoarthritis, Am J Transl Res, 11, 4800
- Brennan, 2022, Weight loss and exercise Differentially affect insulin sensitivity, body composition, cardiorespiratory fitness, and muscle strength in older adults with obesity: A randomized controlled trial, J Gerontol A Biol Sci Med Sci, 77, 1088, 10.1093/gerona/glab240 · DOI · Paper page
- Dieppe, 2005, Pathogenesis and management of pain in osteoarthritis, Lancet, 365, 965, 10.1016/S0140-6736(05)71086-2 · DOI · Paper page
- Gersing, 2017, Is weight loss associated with less progression of changes in knee Articular cartilage among obese and overweight patients as assessed with MR imaging over 48 months? data from the osteoarthritis initiative, Radiology, 284, 508, 10.1148/radiol.2017161005 · DOI
- Anandacoomarasamy, 2012, Weight loss in obese people has structure-modifying effects on medial but not on lateral knee Articular cartilage, Ann Rheum Dis, 71, 26, 10.1136/ard.2010.144725 · DOI
- McAlindon, 2017, Effect of intra-Articular triamcinolone vs saline on knee cartilage volume and pain in patients with knee osteoarthritis: A randomized clinical trial, JAMA, 317, 1967, 10.1001/jama.2017.5283 · DOI · Paper page
- Jüni, 2015, Intra-Articular corticosteroid for knee osteoarthritis, Cochrane Database Syst Rev, 2015
- Solomon, 2010, The comparative safety of Analgesics in older adults with arthritis, Arch Intern Med, 170, 1968, 10.1001/archinternmed.2010.391 · DOI · Paper page
- da Costa, 2021, Effectiveness and safety of non-Steroidal anti-inflammatory drugs and opioid treatment for knee and hip osteoarthritis: network meta-analysis, BMJ, 375, 2321, 10.1136/bmj.n2321 · DOI · Paper page
Cited by
Tang, S., Zhang, C., Oo, W. M., Fu, K., Risberg, M. A., Bierma-Zeinstra, S. M., Neogi, T., Atukorala, I., Malfait, A.-M., Ding, C., et al. (2025) · Nature Reviews Disease Primers · doi:10.1038/s41572-025-00594-6 · Cited by 476
Self-citationOnce-Weekly Semaglutide in Persons with Obesity and Knee Osteoarthritis
Bliddal, H., Bays, H., Czernichow, S., Uddén Hemmingsson, J., Hjelmesæth, J., Hoffmann Morville, T., Koroleva, A., Skov Neergaard, J., Vélez Sánchez, P., Wharton, S., et al. (2024) · New England Journal of Medicine · doi:10.1056/nejmoa2403664 · Cited by 440
Kloppenburg, M., Namane, M., & Cicuttini, F. (2025) · The Lancet · doi:10.1016/s0140-6736(24)02322-5 · Cited by 280
West, S., Scragg, J., Aveyard, P., Oke, J. L., Willis, L., Haffner, S. J. P., Knight, H., Wang, D., Morrow, S., Heath, L., et al. (2026) · BMJ · doi:10.1136/bmj-2025-085304 · Cited by 174
“Beyond cardiometabolic health, there have been suggestions that WMM may be effective for the treatment of osteoarthritis 39 40 and the prevention of cognitive decline, 41 among other conditions.”
The effects of GLP-1 agonists on musculoskeletal health and orthopedic care
Gatto, A., Liu, K., Milan, N., & Wong, S. (2025) · Current Reviews in Musculoskeletal Medicine · doi:10.1007/s12178-025-09978-3 · Cited by 55
Metadata
- Authors
- Zhu, H., Zhou, L., Wang, Q., Cai, Q., Yang, F., Jin, H., Chen, Y., Song, Y., & Zhang, C.
- Venue
- Annals of the Rheumatic Diseases
- Publisher
- Elsevier BV
- Published
- 2023-09
- Volume
- 82
- Issue
- 9
- Pages
- 1218-1226
- ISSN
- 0003-4967 (ISSN-L)
- OpenAlex
- W4378799384
- Cited by
- 129
- References
- 19
- FWCI
- 22.33
- Type
- journal article
- Language
- en
- Open access
- hybrid
- Licence
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- www.elsevier.com/legal/tdmrep-license (tdm)
- creativecommons.org/licenses/by-nc/4.0/ (vor)
- Funders
- National Natural Science Foundation of China (82002324)
- Shanghai Shen Kang Hospital Development Center, Clinical Research Plan of SHDC (SHDC2020CR6019)
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Glucagon-like peptide-1 receptor agonists as a disease-modifying therapy for knee osteoarthritis mediated by weight loss: findings from the Shanghai Osteoarthritis Cohort. https://app.cochat.ai/papers/10.1136/ard-2023-223845
- The paper
- Zhu, H., Zhou, L., Wang, Q., Cai, Q., Yang, F., Jin, H., Chen, Y., Song, Y., & Zhang, C. (2023). Glucagon-like peptide-1 receptor agonists as a disease-modifying therapy for knee osteoarthritis mediated by weight loss: findings from the Shanghai Osteoarthritis Cohort. Annals of the Rheumatic Diseases. https://doi.org/10.1136/ard-2023-223845
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.